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The recent rise in the use of linezolid to treat a variety of resistant pathogens has
uncovered many side effects. Some patients develop lactic acidosis, myelosuppression,
optic or peripheral neuropathies, and myopathies. We evaluated an elderly patient
who presented to the Emergency Room with linezolid toxicity and a novel neurologic
complication characterized by bilateral globi pallidi necrosis. Mitochondrial ribosome
inhibition was described to be the predisposing factor. The patient belongs to the
mitochondrial J1 haplotype known to be associated with side effects of the drug. We
recommend based on the molecular profile of the illness pretreatment considerations
and complication management.
Keywords: linezolid, toxicity, globus pallidus, mitochondria, J1 haplogroup
INTRODUCTION
A 74 years old Caucasian man presented to the Emergency Department because of altered level
of consciousness. He had undergone a recent right knee prosthesis implantation and had been on
antibiotic therapy for 5 weeks for prosthesis infection. Initially, he received 14 days of intravenous
empiric antibiotic therapy and was discharged home on oral linezolid (600 mg orally every 12 h)
and levofloxacin (750 mg orally daily).
On presentation, the patient was in shock with a mean arterial pressure of 54 mmHg and severe
metabolic acidosis (pH = 6.9) with respiratory alkalosis. His anion gap was 37, with a serum
bicarbonate level of 4 mmol/L and a markedly elevated serum lactic acid level of 21 mmol/L.
The patient was afebrile. His white blood cell count (WBC) was 13,300 cells/uL. Severe sepsis
protocol was initiated and he was switched to broad-spectrum antibiotic therapy with meropenem
and vancomycin. Blood and urine cultures were taken. Computed tomography (CT) of the thorax,
abdomen and pelvis were done and did not reveal an active source of infection. A leukocyte scan
of the right knee was negative for active infection. Inflammatory markers including erythrocyte
sedimentation rate (ESR) and procalcitonin were within normal limits, and C-reactive protein
(CRP) level was significantly lower than during prior admissions.
The next day, the patient’s WBC count normalized, but he remained severely acidemic,
requiring one session of hemodialysis and bicarbonate supplementation. Within 48 h of ICU
admission, continuation of antibiotics and aggressive hydration, his blood pH improved to 7.38
despite persistent elevated lactic acid levels (20 mmol/liter). All cultures were negative. Given these
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findings and in the absence of any clinical signs of infection.
Linezolid was considered the cause of the severe lactic acidosis
and antibiotics were discontinued.
On day 4 of hospitalization, the patient developed
pancytopenia with a WBC count reaching 2200 cells/uL,
platelets count of 36,000/uL, and hemoglobin of 8.8 g/dL with
a reticulocyte count of less than 0.3%. The patient’s serum
lactic acid level normalized on day 7 of hospitalization. His
pancytopenia progressively improved and normalized on day 9
with a reticulocyte count of 6.2%.
The patient’s level of consciousness lagged behind; CT
of the brain revealed unexpected hypodensities within the
globi pallidi bilaterally (Figure 1). Magnetic resonance imaging
[MRI and angiography (MRA) of the brain] demonstrated
acute bilateral globus pallidus hyper-intensities consistent with
necrosis (Figure 1). A lumbar puncture was done, and
cerebrospinal fluid (CSF) analysis revealed normal lactate levels
but elevated pyruvate levels 0.108 mmol/l (normal values
between 0.006 and 0.019). Mental status improved slowly,
but the patient remained weak with mainly proximal muscle
weakness. A biopsy was taken from the right vastus lateralis
muscle and showed widespread mitochondrial dysfunction with
marked deficiency in cytochrome C oxidase, increased lipid
globules within myofibers, neurogenic muscular atrophy, and
increased regenerative activity. Further work up (acylcarnitine
profile in blood and urine) was negative for other metabolic
disorders.
Several weeks later, the patient’s symptoms improve drastically
with rehabilitation.
BACKGROUND
Linezolid is a synthetic antibacterial of the oxazolidinone
class. It is used to treat a variety of gram-positive infections,
including methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant enterococci (VRE), Nocardia infections
and multidrug-resistant tuberculosis. It has been lately
encouraged as an alternative therapy in prosthetic infections
(Morata et al., 2014). At times treatment duration is extended
over several weeks. The first case of linezolid-induced lactic
acidosis was described in 2003 (Apodaca and Rakita, 2003).
Lactic acidosis occurs in 6.8% of patients receiving linezolid, and
is particularly associated with longer durations of treatment (Im
et al., 2015).
Linezolid acts by binding to the 23S ribosomal RNA of
bacteria, thus inhibiting bacterial protein synthesis. It acts
preferentially at the A-site of the ribosomal peptidyl transfer
center to inhibit peptide bond formation (Leach et al., 2007;
Wilson et al., 2008). The similarity between bacterial 23S
ribosomal RNA and human mitochondrial 16S ribosomal RNA
(Leach et al., 2007) was hypothesized to be the cause of human
toxicity. In fact, genetic polymorphisms are speculated to be the
main reason behind differential susceptibility to linezolid, and
FIGURE 1 | Computed tomography-scan and MRI of the brain. (A) Shows CT of the brain with bilateral globi pallidi hyper-intensities at day 5 (left) and 14 (right)
from admission. (B) Shows the MRI images documenting acute ongoing stroke on day 6 on T1, T2, and flair captures, respectively.
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nucleotide polymorphism in the mitochondrial 16S ribosomal
RNA in patients with linezolid-associated lactic acidosis has been
reported (Palenzuela et al., 2005; Carson et al., 2007; Song et al.,
2015)
Here we describe a patient with clinical and biochemical
features secondary to linezolid toxicity secondary to a
mitochondrial disorder.
METHODS
Genetic and Enzymatic Studies
This study was approved by the American University of Beirut
Institutional Review Board (Protocol Number: PBK11). One
patient with linezolid-induced toxicity was recruited with written
informed consent from the wife and children. Blood was taken
for genetic analysis by dideoxy sequencing of previously reported
haplogroup-defining regions. Spectrophotometric analysis of
mitochondrial respiratory chain oxidative phosphorylation
complexes was performed (El-Khoury et al., 2013) and compared
to results of histochemical staining of muscle biopsy.
RESULTS
Biomolecular Basis of Toxicity
The histochemical evaluation of the activity of all mitochondrial
respiratory chain enzymes showed significant reduction of
cytochrome oxidase (COX) enzymatic activity (Figures 2A,B).
COX staining revealed a more severe loss of activity on
FIGURE 2 | Histochemical staining and spectrophotometric activity of respiratory chain enzymes. (A) and (B) Show histopathologic stains of vastus
lateralis muscle illustrating activities of NADH, COX (cytochrome oxidase), SDH, and COX/SDH in patient (A) and Control (B). (C) Spectrophotometry measurements
of specific activities of CI (NADH dehydrogenase), CII (Succinate dehydrogenase), CIII (Cytochrome bc1), CIV (cytochrome oxidase), and CV (ATP synthase) show
marked drop of respiratory chain complexes activities in patient compared to control. (D) Citrate synthase (CS) specific activity measured as reference enzyme,
which reflects the total mitochondrial mass. (E) Ratios of the absolute activities of the different complexes corrected to CS activity. Biochemical assessments were
performed twice with the same control muscle biopsy used as a positive control. The patient’s enzymatic activities (nearly identical in both analyses) were far below
the lower limit of our reference ranges.
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histochemical stains than observed for other mitochondrial
respiratory chain enzymes. This loss was also evident
when the specific activity of each complex was assessed
spectrophotometrically on patients’ muscle homogenate
preparation. Indeed, we have shown that all mitochondrial
respiratory chain complexes activities, but complex II (which
is completely encoded from the nucleus), are depressed in
the patient, with more severe loss in Complexes IV and V
(Figures 2C–E).
Gentic Basis of Toxicity
Sanger sequencing of the mitochondrial DNA was carried on
our patient and the results were compared to available electronic
databases as well as previously reported susceptibility loci. Our
patient belongs to the J1 mtDNA haplogroup. This haplogroup
is carried by 9.2% of non-hispanic whites in the United States
(Mitchell et al., 2014) and 8–9% of the European population.
DISCUSSION
Linezolid toxicity is associated with 26% mortality (Im et al.,
2015). The high incidence of death in patients with severe toxicity
reflects such a systemic mitochondrial cytopathy with multi-
organ dysfunction.
Linezolid interferes directly with mitochondrial protein
synthesis and therefore with respiratory chain activity (Nagiec
et al., 2005; Soriano et al., 2005). This results in severe
clinical consequences such as lactic acidosis, myelosuppression,
and peripheral and ocular neuropathies. This occurs due to
severe mitochondrial dysfunction in highly active cells. The
effect of linezolid on the neurologic system are not well-
determined; a very small number of case reports showed the
potential of linezolid to induce optic neuropathy, peripheral
neuropathy, and encephalopathy (Ferry et al., 2005; Nagel
et al., 2007; Narita et al., 2007; Fletcher et al., 2010). The
previous reported cases of encephalopathy were transient,
sometimes related to other coexisting sedating drugs (Ferry
et al., 2005) and with negative brain MRI findings (Ferry
et al., 2005; De Vriese et al., 2006; Fletcher et al., 2010).
However, there are no prior reported cases of linezolid-
induced stroke-like lesions in the globi pallidi bilaterally
as in our patient. Stroke-like episodes are episodic events
described previously with mitochondrial disorders – most
frequently with MELAS syndrome (Goodfellow et al., 2012),
Leigh’s encephalopathy and carbon monoxide or cyanide
poisoning. Neurological manifestations occur late and are likely
due to the weaker penetration to the brain tissue, while
myelosuppression and myopathy tend to appear earlier. Most
of the mitochondrial abnormalities normalize after linezolid
withdrawal, with lactate normalization and clinical recovery as
has occurred in this case and previously reported cases (Garrabou
et al., 2007).
Various presentation of linezolid toxicity is secondary to
varying ribosomal susceptibility. The mitochondrial haplogroup
(J1 in our case) determines the cause, while the cumulative
treatment duration dictates the spectrum. Certain mitochondrial
haplogroups are more susceptible to linezolid effect than others
(Pacheu-Grau et al., 2013); in vitro, the polymorphism decreases
synthesis of mtDNA-encoded polypeptides in cells treated with
linezolid. The J1 defining SNPs are close to the ribosomal peptidyl
transferase center. This proximity and phenotype picture links
the susceptibility hypothesis with molecular basis of toxicity.
The prevalence of J1 haplogroup suggests that 8–9% of US
and European patients are at risk of developing complications
described above.
Patients present with severe lactic acidosis mimicking
septic shock, develop myelosuppression, optic or peripheral
neuropathies, and myopathies, and central nervous system
disease as documented in this report–a picture suggestive of
an acquired mitochondrial syndrome. Differentiating linezolid
toxicity from septic shock and cerebrovascular events is essential
in improving survival and patient outcome.
Hints such as bilateral globi pallidi lesions and abnormally
high lactic acid levels (greater than 20 mmol/L) should not
defer antibiotic therapy for other infective processes. However,
careful choices of antibiotics in this population is required;
vancomycin, for example, is also known to inhibit complex I of
the respiratory chain (Arimura et al., 2012), and may result in
additional mitochondrial dysfunction.
CONCLUSION
Linezolid toxicity is associated with significant morbidity and
mortality. It mimics septic shock delaying diagnosis. Up to
9% of Western population could be at risk. Bilateral globi
pallidi necrosis presents in linezolid toxicity in the setting of
systemic mitochondrial cytopathy. We recommend screening
for J1 mitochondrial haplogroup in patients considered for
prolonged therapy with the drug.
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